EGFR inhibitors (EGFRis) are targeted agents which provided a major advance in the management of many malignant tumors including colorectal cancer [2], head and neck squamous cell carcinoma [3], nonsmall-cell lung cancer [4], breast cancer [5], and pancreatic cancer [6]. This evidence concerns the gene EGFR and cancer.